Escend Pharmaceuticals, Inc.
3475 Edison Way suite R
Menlo Park, CA 94025
Our mission is to develop therapeutics for oncology orphan indications by ablating cancer stem cells. Our business model is to reduce drug development risk by leveraging on previous data. We select foreign-approved drugs with established safety and match them to appropriate indications, where their effects on cellular survival and activation pathways can be exploited for the development of novel drugs. This is not repurposing and our products would have new molecular entities (NMEs) status in the United States. Our lead agent, ES-3000, is in current clinical use (ex-US) as an anti-inflammatory. We are developing ES-3000 for chronic myeloid leukemia (CML) as it inhibits CML stem cells by reducing β-catenin expression through a novel mechanism of action. Wnt/β-catenin is critical in the development of cancer stem cells. ES-3000 has been granted orphan drug designation by the FDA for the treatment of CML. At present, Escend has 6 provisional patent applications covering two products for CML, acute myeloid leukemia (AML) and triple negative breast cancer (TNBC) and pancreatic cancer. The company has completed freedom to operate analysis on ES-3000. We are seeking industry partners to form early stage alliances and partnerships to support development and commercialization of our lead agents.
Oncology, hematologic malignancies, chronic myelogenous leukemia, acute myeloid leukemia, triple negative breast cancer (TNBC)
Drug Delivery Technologies
Discovery and Development - Small Molecu
Clinical Development Stage